These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Chia AYT; Ang GWX; Chan ASY; Chan W; Chong TKY; Leung YY Front Med (Lausanne); 2021; 8():737256. PubMed ID: 34604268 [TBL] [Abstract][Full Text] [Related]
27. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Novelli L; Lubrano E; Venerito V; Perrotta FM; Marando F; Curradi G; Iannone F Front Med (Lausanne); 2021; 8():737079. PubMed ID: 34631754 [TBL] [Abstract][Full Text] [Related]
29. A Review for Physician Assistants and Nurse Practitioners on the Considerations for Diagnosing and Treating Psoriatic Arthritis. Giannelli A Rheumatol Ther; 2019 Mar; 6(1):5-21. PubMed ID: 30570707 [TBL] [Abstract][Full Text] [Related]
30. Psoriatic arthritis as a distinct disease entity. Leung YY; Tam LS; Kun EW; Li EK J Postgrad Med; 2007; 53(1):63-71. PubMed ID: 17244977 [TBL] [Abstract][Full Text] [Related]
31. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. Chan J; Gladman D Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312 [TBL] [Abstract][Full Text] [Related]
32. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Tobin AM; Kirby B BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217 [TBL] [Abstract][Full Text] [Related]
34. Disease Profile and Achievement of Therapeutic Goals in a Modern, Nationwide Cohort of 923 Patients with Psoriatic Arthritis. Fragoulis GE; Papagoras C; Gazi S; Mole E; Krikelis M; Voulgari PV; Kaltsonoudis E; Koletsos N; Katsimpri P; Boumpas D; Katsifis D; Kougkas N; Dimitroulas T; Sfikakis PP; Tektonidou MG; Gialouri C; Bogdanos DP; Simopoulou T; Koutsianas C; Mavrea E; Katsifis G; Kottas K; Konsta M; Tziafalia M; Kataxaki E; Kalavri E; Klavdianou K; Grika EP; Sfontouris C; Daoussis D; Iliopoulos G; Bournazos I; Karokis D; Georganas K; Patrikos D; Vassilopoulos D Mediterr J Rheumatol; 2023 Dec; 34(4):418-426. PubMed ID: 38282940 [TBL] [Abstract][Full Text] [Related]
35. Outcome measures in psoriatic arthritis. Gladman DD; Mease PJ; Healy P; Helliwell PS; Fitzgerald O; Cauli A; Lubrano E; Krueger GG; van der Heijde D; Veale DJ; Kavanaugh A; Nash P; Ritchlin C; Taylor W; Strand V J Rheumatol; 2007 May; 34(5):1159-66. PubMed ID: 17477479 [TBL] [Abstract][Full Text] [Related]
36. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. van der Heijde D; Gladman DD; Kavanaugh A; Mease PJ Arthritis Res Ther; 2020 Feb; 22(1):18. PubMed ID: 32014044 [TBL] [Abstract][Full Text] [Related]
37. Peripheral spondyloarthritis: Concept, diagnosis and treatment. Molto A; Sieper J Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):357-368. PubMed ID: 31171308 [TBL] [Abstract][Full Text] [Related]
38. Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. Laires PA; Carrilho M; Tavares-Costa J; Lucas P; Machado P; Cunha-Miranda L; Pimentel-Santos F; Santos H; Vieira-Sousa E; Santos MJ Acta Reumatol Port; 2020; 45(1):46-57. PubMed ID: 32578579 [TBL] [Abstract][Full Text] [Related]
39. Janus kinase inhibitors for the treatment of psoriatic arthritis. Raychaudhuri S; Jayeshbhai Shah R; Raychaudhuri SK; Raychaudhuri SP Indian J Dermatol Venereol Leprol; 2023 Jul; ():1-6. PubMed ID: 37609752 [TBL] [Abstract][Full Text] [Related]